Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AON-D21 single ascending dose study in healthy men
NCT05018403Phase 1Completed
- Sponsor
- Aptarion Biotech
- Start
- Aug 2021
- Primary completion
- Jan 2022
- Modality
- Antisense DNA, RNA Aptamers, Small Interfering RNA (siRNA)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in community acquired pneumonia (CAP) and paroxysmal nocturnal hemoglobinuria (PNH) comparing AON-D21 with Placebo (2 arms). Primary endpoint: Treatment-Emergent Adverse Events at 14 days. Started Aug 2021; status: completed.
02
Drugs
AON-D21
03
Conditions
community acquired pneumonia (CAP)paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT05018403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05018403.